Rheumatoid arthritis (RA) is believed to be an autoimmune disease mainly caused by the longstanding observation of the presence of increased levels of autoantibodies. The classical autoantibodies are rheumatoid factors (RFs), i.e., antibodies reactive with IgG. Although these are likely to be relevant, as their occurrence predates the development of clinical arthritis ( 1 ) , it is still unclear what their pathophysiologic role is. However, one of the most exciting recent discoveries is the fi nding that antibodies recognizing citrullinated proteins show a higher specifi city for RA as compared with RFs ( 2, 3 ) . Citrullination is a posttranslational modifi cation of proteins in which a peptidyl arginine is converted into the nonstandard amino acid peptidyl citrulline. The reaction is catalyzed by calcium-dependent peptidyl arginine deiminase (PAD), an evolutionarily conserved protein with several isoforms in both mice and humans (PAD1 -4 and PAD6) ( 4 ) . The most prominent diff erence between the distinct PAD isotypes is the distribution of expression among specifi c tissues. PAD4 can be found in monocytes and macrophages, whereas both PAD2 and PAD4 have been observed in synovial fl uid ( 5 -7 ) . Citrullination has been detected in many tissues and has been shown to occur in both mouse and human infl amed joints ( 5, 8, 9 ) . Not only the expression but also the activation of PAD is required for citrullination. This activation requires a local calcium concentration of ‫ف‬ 10 Ϫ 5 mol/liter, which is much higher than normal cytosolic calcium concentration ( ‫ف‬ 10 Ϫ 7 mol/ liter) ( 7 ) . However, the calcium concentration is increased in the cytoplasm during apoptosis Importantly, mice expressing the RA associated DR4 or DR1 class II molecules are also susceptible to arthritis because of recognition of an almost identical glycopeptide (CII261-273). In fact, T cell responses to this peptide, in particular to the galactosylated form, are raised in RA ( 20 ) . Both mouse and human T cells predominantly recognize the posttranslationally modifi ed lysine side chain at position 264. The B cell response in the CIA model is directed to a series of epitopes located at the triple helical form of the CII molecule, and these epitopes are also conserved and recognized in RA ( 23 ) . Antibodies to certain epitopes correlate with arthritis severity in both CIA and RA, and mAbs directed to these epitopes induce arthritis in mice (the so-called collagen antibody -induced arthritis [CAIA] ). Interestingly, these triple helical epitopes on the CII molecule contain a conserved motif that contains an arginine (G-X-R-G hydrophobic amino acid). In fact, some of the defi ned epitopes contain the conserved motifs in a tandem repeat like the dominating " C1 " epitope at position 359 -370 ( 24 ) . Clearly, this opens up the possibility that these arginines could be citrullinated, exposing a second type of posttranslationally modifi ed epitope in addition to the galactosylation of lysine 264 recognized by T cells. We have recently demonstrated that one of the major B cell epitopes on CII, the C1 epitope CII 359 -370 (GARGLTGRPGDA), is also recognized in RA in its citrullinated form ( 25 ) .
We have now made a panel of mAbs against the citrullinated C1 epitope and show that both CII-and citrulline-specifi c antibodies induce as well as promote arthritis in the mouse. Using these antibodies, citrullinated CII can be identifi ed in mouse and human RA joints. The structural interactions between one of the antibodies recognizing the citrullinated epitopes were revealed, and it was found that the peptide forms a hairpin exposing the citrulline side chain into the combining site of the antibody. These data thus demonstrate that citrullination of CII occurs in RA, and the antibodies specifi c for at least one of the citrullinated collagen epitopes induces and promotes the development of arthritis.
RESULTS

Generation and specifi city of mAbs to citrullinated CII ACC1 -5
The mAb ACC1, specifi c for citrullinated CII, was isolated from a B10.RIII Cia5 congenic mouse immunized with bovine CII. The ACC2 -4 antibodies were raised from DBA/1 or (B10.Q × DBA/1) F1 mice immunized with PAD4-treated B+T-Cit peptides emulsifi ed in CFA. GB8 and ACC5 stem from B10.Q mice with chronic arthritis after CII/CFA immunization. The cloned hybridomas were characterized by VDJ sequencing, and the mAbs were purifi ed and tested for specifi city ( Fig. 1 a and Table I ).
Sequencing revealed that ACC1, ACC4, GB8, and UL1 have unique cDNA V gene sequences, whereas the ACC2 and ACC3 clones shared both V H and V L (Figs. S1 and S2, available at http://www.jem.org/cgi/content/full/ jem.20081862/DC1). The ACC2 and ACC3 clones were derived from the same mouse and are therefore likely to or necrosis ( 10 ) , which allows PAD to be released. In infl amed tissues, the released PAD could therefore also citrullinate extracellular proteins like fi brinogen and collagen.
Antibodies against citrullinated proteins (ACPAs) have been identifi ed in the synovium of a high number of RA patients (50 -70%) ( 11, 12 ) . In contrast, ACPAs are rarely found in healthy individuals or patients with other diseases ( < 2%). Interestingly, ACPAs share with RFs the fact that they can be detected in patient sera even before the onset of initial RA symptoms, and are therefore believed to play a pathogenic role ( 13 ) . These fi ndings have stimulated the search for the origin of ACPA production. The recognition of citrulline is dependent on the protein backbone, and it has therefore been of considerable interest to identify proteins that elicit and perpetuate the ACPA response. Clearly, ACPAs are produced in the joints ( 11, 14 ) , and one possibility is that the recognized citrulline is an antigenic determinant that is preferentially associated with proteins deposited in joints like fi brin ( 15 ) . In fact, immunization of mice with citrullinated fi brin has been reported to induce joint infl ammation, which, however, differs considerably in its histopathologic features from those that are characteristic of RA or its well-established experimental models, such as collagen-induced arthritis (CIA) ( 16 ) . In addition, fi brin deposition is not specifi c for RA joints ( 17 ) . An alternative hypothesis is closely related to the discovery that citrullination of a vimentin-derived peptide increases its binding to the RA-associated MHC class II molecule DR4 ( 18 ) . Similar to previous discoveries in celiac disease, the posttranslational modifi cation of a potential T cell determinant could explain the breakdown of self-tolerance ( 19 ) . Although tolerance remains restricted to the nonmodifi ed self, it could easily allow for T cell activation in response to a presented citrullinated self-determinant, thereby giving rise to autoantigen-specifi c B cell help. However, so far there is no evidence for an enhanced T cell response to citrullinated vimentin neither in RA nor in animal models. An alternative perspective on the potential mechanism that may lead to the development of humoral immunity to citrullinated self-proteins in RA is off ered by the assumption of a so-called linked recognition. According to this concept, the B cells with specifi city for a citrullinated determinant get activated upon cooperation with T cells recognizing another (nonmodifi ed cryptic) epitope on the same protein. In fact, the major cartilage protein, collagen type II (CII), provides such a possibility for recognition as a relevant joint-specifi c autoantigen. Importantly, if a linked recognition occurs, it could operate in two steps; i.e., B cells producing antibodies to other citrullinated proteins may capture citrullinated CII and subsequently activate pathogenic CII-reactive T and B cells. In this case, a response to CII should occur in RA joints.
Immunization of genetically susceptible animals with CII induces arthritis and is the basis for one of the most commonly used animal models for RA, CIA. The critical immune recognition structures have been identifi ed in the mouse ( 20 -22 ) . T cells recognize a glycopeptide derived from CII position 260 -270 on the MHC class II molecule A q . (a) ACC mAb specifi city in ELISA. Several arginine-containing peptides and their citrulline analogues have been tested to characterize the citrulline specifi city of our generated antibodies. Some of the epitopes were accessible in the triple helical form of the citrulline-containing C1 III epitope (THPCII-Cit) for some of the antibodies (ACC1 -3 and ACC5; A and B). Nevertheless, this epitope seems not to be accessible for ACC4. Some of the antibodies cross react to selected citrullinated peptides even with a noncollageneous backbone. ACC2, ACC3, and ACC5 bind not only to CII but also to the citrullinated derivative of fi brinogen (C and D). Furthermore, ACC4 and ACC5 bind stronger to the citrullinated form of cyclic fi laggrin (cyc-Cit) than to its arginine-containing form (cyc-Arg; E and F). Enzymatic deimination of CII with PAD4 generates neoepitopes, which are recognized by ACC2 -4 (G -I). C1 III peptides containing an additional biotinylated lysine have been synthesized, which in turn bind to NeutrAvidin-precoated ELISA plates (J -M). This setup allows free accessibility of the different antibodies specifi c for the citrulline-modifi ed immunodominant CII epitopes. All of the assays were done in duplicate. (b) Staining of arthritic joints. Citrulline-specifi c antibodies bind to arthritic cartilage. Joint sections (10 mm) from arthritic BALB/c (A, C, and D), naive (BALB/c × B10.Q) F1 (B), or BALB/c (E) mice are shown. Results shown are representative histological pictures of arthritic ( n = 4) and control ( n = 3) mice used in the staining of joints with anticitrulline antibodies. Arthritis was induced in 4 -6-mo-old naive male BALB/c mice ( n = 36) by injecting 9 mg of an arthritogenic anti-CII mAb cocktail containing antibodies M2139 (binding to the J1 epitope) and CIIC1 (binding to the C1 I epitope). The arthritis induction experiment was performed four times independently with 100% incidence and a mean maximum arthritis score of 32.9 ± 3. The four mice that were used for histology had arthritis scores of 59, 60, 47, and 50. Paw samples were taken on day 11 after antibody transfer (5 d after LPS injection). Sections were treated with no antibodies (A), ACC1 (B), or ACC4 (C -E) mAbs. Magnifi cation, × 10.
CII IgG antibodies M2139 (recognizing the J1 epitope), CIIC1 (recognizing the C1 I epitope), and UL1 (recognizing the U1 epitope), and injected them in vivo in both naive mice and mice suff ering from chronic CIA ( Fig. 2 ; and Tables II and III ) . The ACC1 antibodies could induce mild arthritis in naive mice, and a more severe form of the arthritis was developed after a booster injection of LPS, similar to pathogenic anti-CII antibodies ( Fig. 2 a ) . The severity of arthritis was enhanced when the ACC1 antibody treatment was combined with the anti-CII antibodies M2139 or CIIC1 (unpublished data). As the induction of arthritis with ACC1 could possibly be caused by its cross-reactivity with denatured CII, we also used the ACC4 antibody that showed no cross-reactivity with nonmodifi ed CII and recognized the citrulline epitope on a single ␣ -chain peptide. Injection of ACC4 antibody enhanced the arthritis when given concomitantly with another CII-specifi c antibody (M2139 ACC4) but could not induce arthritis by itself ( Fig. 2 a ) . This lack of direct arthritogenic potential could be caused by the noncomplement-binding subclass of the ACC4 antibody (IgG1). Another citrulline-specifi c antibody, the IgM ACC5 mAb preferentially recognizing the noncollagenous citrullinated antigens fi laggrin and fi brinogen, induces arthritis but with very low severity ( Fig. 2 b ) . The monoclonal IgG2b antibody GB8 that recognized denatured CII was also unable to enhance arthritis in combination with anti-CII antibodies ( Fig. 2 a ) . We conclude that antibodies to citrullinated CII can induce arthritis in naive mice by themselves, and the arthritis severity is enhanced by combining them with antibodies to noncitrullinated CII.
To test whether the ACC antibodies could trigger a relapse of arthritis in an already ongoing chronic arthritis, we used a model in which chronic arthritis was induced in (BALB/c × B10.Q) F1 mice. These mice develop a chronic relapsing disease with a duration of > 200 d, and we selected mice in remission from a large cohort of mice. Anti-CII antibodies induce arthritis relapses 1 -2 d after injection in this cohort. Similarly, both ACC1 and ACC4 could both induce originate from the same clone in vivo. All of these ACC antibodies contained somatic mutations, indicating that they are produced by T cell -dependent follicular B cells (Table S1 ). All ACC antibodies bind to citrullinated forms of the C1 epitope. ACC1 -3 and ACC5 bind to the triple helical citrullinated C1, and ACC4 binds to the citrullinated C1 epitope as an ␣ -chain peptide. None of the ACC antibodies cross react to the respective noncitrullinated variant of the ␣ chain of the C1 epitope. However, they cross react with variable degrees to citrullinated epitopes on other peptide backbones. ACC4 and ACC5 bind to cyclic citrullinated fi laggrin peptide (i.e., CCP1), and ACC2 and ACC3 bind to citrullinated fi brinogen. Thus, these antibodies are mouse monoclonal ACPAs. Although they are all directed to the citrullinated C1 epitope, their specifi cities are not identical. The ACC1 antibody cross reacted to denatured CII as well as to the denatured triple helical C1 epitope. There are two arginines in the C1 epitope, which can be posttranslationally converted to citrulline. ACC2 -4 recognize the fi rst citrulline at position 360, and ACC1 recognizes the second citrulline at position 365.
To determine whether the citrullinated epitope is exposed in vivo, we stained joint sections from adult arthritic mice using the ACC1 and ACC4 antibodies. The ACC1 antibody stained cartilage and the ACC4 antibody stained the infl amed synovial tissue in the vicinity of cartilage ( Fig. 1 b ) . Although the staining with ACC4 clearly demonstrates the occurrence of citrullinated denatured CII in the cartilage, the interpretation of the ACC1 staining is less clear because it might refl ect either antibody recognition of citrullinated CII or cross-reactive binding to the denatured CII.
Induction of arthritis
To investigate the arthritogenic potential of the ACC mAbs, we purifi ed the ACC1 (an IgG2c specifi c for triple helical C1 epitope), ACC4 (an IgG1 specifi c for the citrullinated C1 epitope on the ␣ chain), and ACC5 antibodies (an IgM specifi c for the triple helical C1 epitope), as well as the anti- 
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bodies. We conclude that not only anti-CII antibodies but also antibodies specifi c for citrullinated CII induce relapses during the chronic phase of arthritis.
arthritis and enhance severity in this situation ( Fig. 2 b ) . The induction of an arthritic relapse was, however, less pronounced but more prolonged as compared with anti-CII anti- Figure 2 . Citrulline-specifi c antibodies mediate arthritis. (a) The frequency of arthritis on different days is shown. Groups (ACC1, n = 14; ACC4, n = 10; M2139 + PBS, n = 33; M2139 + ACC3, n = 10; M2139 + ACC4, n = 28; M2139 + ACC5, n = 10; M2139 + CIIC1, n = 20; and M2139 + GB8, n = 10) of 4-mo-old naive male B10.RIII mice were injected i.v. with 9 mg of a single mAb or an equal combination of two mAbs. M2139 with CIIC1 and 4.5 mg M2139 with PBS constituted positive and negative controls, respectively. 25 μ g LPS per mouse was injected i.p. on day 5 to enhance the incidence and severity of arthritis. Results shown are pooled values from three similar experiments with balanced groups. M2139 + ACC4 versus M2139 + PBS, P ≤ 0.0113 (days 3 -4) and P ≤ 0.001 (days 5 -27); ACC1 versus ACC4, P ≤ 0.0034 (days 10 -14 and days 21 -27) and P ≤ 0.0013 (days 17 -19). *, P < 0.05; **, P < 0.005; and ***, P < 0.001. (b) 2-mo-old QB = (BALB/c x B10.Q) F1 mice were injected with CII + CFA on day 0 and boosted with CII + IFA on day 35. These mice developed chronic arthritis that persisted for a minimum of 210 d. Mice that had no arthritis after 210 d were injected with 9 mg of a single mAb or an equal combination of two mAbs constituted different groups (ACC4, n = 9; PBS, n = 20; M2139 + PBS, n = 7; UL1 + PBS, n = 8; M2139 + ACC4, n = 10; and UL1 + ACC4, n = 9). M2139 with CIIC1 or UL1 and 4.5 mg M2139 or UL1 with PBS constituted positive and negative controls, respectively. LPS was not injected in these mice. The PBS-injected group denotes spontaneous relapse. All of the mice were used for calculations. Results shown are pooled values from two similar experiments with balanced groups. M2139 + ACC4 versus M2139 + PBS, P ≤ 0.026 (day 13) and P ≤ 0.026 (day 15); UL1 + ACC4 versus UL1 + PBS, P ≤ 0.0311 (day 5). *, P < 0.05 indicates a signifi cant increase in arthritis frequency induced by ACC4 antibodies.
plex with a collagen C1 peptide citrullinated at position 360 (peptide pCII-Cit1) were determined, and data and refi nement statistics are shown in Table IV . The Fab -peptide complex crystal belongs to space group P2 1 , with two independent molecules per asymmetrical unit. The crystal of the ACC4 Fab alone has space group P2 1 2 1 2 1 , with one molecule per asymmetrical unit. The overall structure of ACC4 ( Fig. 4 a ) is similar to other Fab fragments for which the structure is known. The Fab fragment contains four Ig fold domains: two for the heavy chain (V H and C H ) and two for the light chain (V L and C L ). Each domain consists of a stable arrangement of hydrogen-bonded, antiparallel ␤ strands, further stabilized by disulfi de bond bridges between L23-L93, L139-L199, H22-H96, and H145-H200. The variable domains contain nine ␤ strands and the constant domains contain seven ␤ strands. The binding pocket is formed by residues from complementary determining region (CDR) loops H1, H2, H3, L1, L2, and L3 of the Fab fragment. CDR loops L1, L2, L3, H1, and H2 fall into canonical classes 4, 1, 1, 1, and 2, respectively ( Table V ) . The elbow angle of the ACC4 peptide complex was determined by RBOW ( 26 ) as being 184.5 ° for the fi rst molecule in the asymmetrical unit and 188.6 ° for the second, whereas the elbow angle of the unliganded Fab is 181.6 ° . These values are within the range (127 -227 ° ) for known Fab models.
Conformation of the bound citrullinated collagen peptide
The Fo-Fc maps revealed a clear density for bound peptide and allowed us to build 9 out of 18 residues unambiguously (A5-Cit6-G7-L8-T9-G10-R11-HyP12-G13; Fig. 4 b ) . The ordered part of the peptide corresponds to the C1 (359 -367) epitope on CII. The second Fab molecule is relatively more disordered, and therefore only seven residues of bound peptide (Cit6-G7-L8-T9-G10-R11-HyP12-) are ordered; however,
Immunoprecipitation of citrullinated CII from human RA and osteoarthritis (OA) joints
To determine whether citrullination of CII also occurs in human RA, we immunoprecipitated CII from synovial fl uid ( Fig. 3 a ) . For screening of citrullinated CII in 72 synovial fl uid specimens from patients with OA ( n = 47), RA ( n = 10), and reactive arthritis (Reac A; n = 15), a capture ELISA procedure was designed. The titer plates were coated with a mixture of three earlier characterized mAbs (CIIE10, M2139, and D3) ( 24 ) recognizing distinct epitopes on native CII to capture the triple helical CII from the synovial fl uid for subsequent detection with the biotinylated mAb ACC2 in combination with avidin-peroxidase. Citrullinated CII was detectable in synovial fl uid from 7 out of 10 RA-and 20 out of 47 OA-derived samples (OD values > mean + 2SD of BSA control), whereas the results remained negative for all of the 15 specimens collected from Reac A patients, usually representing a nonerosive form of joint infl ammation that does not lead to CII degradation ( Fig. 3 b ) . For specifi city control of the ELISA procedure, immunoprecipitation of selected synovial fl uid samples was performed using the described cocktail of anti-CII mAbs followed by SDS-PAGE and immunostaining. Thus, precipitated CII was blotted onto a nitrocellulose membrane for subsequent detection of the CII-citrulline residues after a specifi c chemical modifi cation procedure with an antimodifi ed citrulline monospecifi c antibody ( Fig. 3 a ) . In addition, a gel staining of citrullinated CII was performed using the specifi c mAb ACC2 as a detecting reagent ( Fig. 3 b ) .
Molecular structure of ACC4 complexed with the citrullinated C1 epitope To investigate the molecular interactions between the mAbs and citrullinated CII, we selected the ACC4 antibody that recognized the citrullinated CII single-chain peptide. The structure of the ACC4 (IgG1/ ) Fab fragment and its com- Groups of 4-mo-old naive male B10.RIII mice were injected i.v. with 9 mg of a single mAb or an equal combination of two mAbs. M2139 with CIIC1 and 4.5 mg M2139 with PBS constituted positive and negative controls, respectively. 25 μ g LPS per mouse was injected i.p. on day 5 to enhance the incidence and severity of arthritis. Cumulative incidence: M2139 + ACC4 versus M2139 + PBS, P ≤ 0.0006; and ACC1 versus ACC4, P < 0.001. Maximum arthritis score: M2139 + ACC4 versus M2139 + PBS, P < 0.0001; and ACC1 versus ACC4, P = 0.0024. Results shown are pooled values from three similar experiments. **, P < 0.005; ***, P < 0.001; and ****, P < 0.0001. hydrophobic moiety of the citrulline side chain interacts with Trp50H, which is a framework (FRH2) residue. The tip of the peptide (Leu8P and Thr9P) has hydrophobic contacts with CDRL3 (Gly96L, Phe99L, and Leu101L) and with the heavy-chain second framework residues Trp47H and Trp50H. Another framework residue, Thr59H (FRH3), contacts with Leu8P via a bridging water molecule in the interface. Thr9P forms a hydrogen bond with Glu104H. The arginine (Arg11P) is located in the middle of the C-terminal half of the peptide and provides the most extensive interactions by making contacts with 11 diff erent residues of the Fab ( Fig. 4 d ) . The negatively charged residues from the light chain, Asp31L and Asp33L, are in close proximity to Arg11P, but the distance is too large to form a salt bridge. Although there is not a proper salt bridge, Arg11P contacts with Glu104H (CDRH3) and has cation -interactions with Tyr37L (CDRL1). Arg11P forms a single hydrogen bond the conformation of the peptide is virtually the same as the for the one in the other molecule. The overall conformation of both pCII-Cit1 peptides is similar to a ␤ hairpin with a type II ␤ turn on the tip formed by Leu8P and Thr9P. The conformation of the peptide is stabilized by a network of intra-and interchain hydrogen bonds together with polar, apolar, and hydrophobic interactions. This conformation provides an overall cyclic shape to the peptides.
There (Fig. S3 , available at http://www.jem.org/cgi/content/full/ jem.20081862/DC1). Although the second peptide complex in the asymmetrical unit is more disordered, electron density of this water is present at lower levels. The plane of the hairpin is perpendicular to plane of the paratope cavity; therefore, only the lower edge and the tip of the hairpin plane are interacting with the Fab, whereas the upper edge is mostly solvent exposed. Arg11P, HyP12P, and Gly13P at the C terminus are twisted away from the ␤ structure because a rotation of the C ␣ -C Ј bond of Gly10P causes the carbonyl oxygen of Gly10P to be directed to the exterior rather than to the interior part ( Fig. 4 c ) .
Fab -peptide interactions
The pCII-Cit1 peptide fi lls a groove in the antibody-combining site, which is surrounded by the CDR loops. The Cterminal half of the peptide has more extensive contacts with the Fab because this half is buried into the Fab, whereas the N-terminal half is partially exposed to the solvent and has fewer contacts with the Fab. The buried accessible surface areas ( ⌬ BSAs) on the Fab and the peptide are 549.1 and 720.4 Å 2 , respectively. The ⌬ BSA on the Fab is formed mainly by the heavy chain (69.3%) involving CDRH1 (17.2%), CDRH2 (7.5%), FRH2 (19.1%), FRH3 (1%), and CDRH3 (24.6%), and the light chain (30.7%) involving CDRL1 (8.1%) and CDRL3 (22.3%; calculated using PISA software at EMBL-EBI) ( 27 ) . The CDRL2 loop did not have any contact with the peptide. Although Ala5P has clear electron density, this residue does not form any contacts with Fab. The remaining eight visible residues of the peptide have contacts with CDR loops and framework residues ( Table V ) .
Citrulline (Cit6P) is the second residue in the visible part of the pCII-Cit1 peptide. Although the N-terminal side of the peptide hairpin has only a limited number of interactions with the Fab, the citrulline side chain is involved in the most of these interactions ( Fig. 4 d ) . Citrulline interacts with CDRH1, CDRH2, and FRH2. Thr30H, Asp31H, Tyr32H, and Ser33H from CDRH1 contact with citrulline with their main-chain atoms. These interactions are mainly Van der Waals interactions. The backbone carbonyl oxygen of Thr30H also forms a hydrogen bond with citrulline (N8). Citrulline is further stabilized by hydrogen bonds with the side chain of the residue Thr53H (N and OG1; Fig. 4 d ) . The with the carbonyl oxygen of Gly96L. The CDRH3 loop contacts Arg11P with all of its residues. Hydroxyproline (Hyp12P) is involved in Van der Waals interactions with Ala99H, Thr100H, and Thr101 (CDRH3). Gly13P has contacts with Tyr32H and Asp31H.
The comparison of the peptide bound and unliganded Fab structures reveals that no signifi cant conformational changes are required for binding. The overall root mean square deviation for the variable domains of the two structures is only 0.47 Å . There are only minor diff erences in the side-chain orientations of residues, which are close to the contact interface. Therefore, the binding of peptide follows the key-lock mechanism that requires a structurally stable antibody-combining site.
DISCUSSION
Antibody formation against CII is not only a common autoimmune phenomenon in RA but may also have pathogenic consequences. We now show that CII is citrullinated in the joints and that an antibody response to such epitopes could be a pathogenic link to CII autoimmunity. The present study provides the fi rst molecular insights into how antibodies recognize a citrullinated epitope and the functional consequence of such an interaction. Mouse B cell hybridomas with specifi cities for citrullinated variants of the immunodominant CII epitope were established, and the respective mAbs were used to demonstrate their arthritogenicity in transfer experiments to naive mice as well as for the detection of citrullinated CII in human joints. Our systematic analysis of the pathogenicity of these mAbs is also the fi rst study in the area of APCA research that provides a detailed characterization of the antibody fi ne specifi cities, including their relevant cross-reactivities. Because the availability of the latter information is critical for interpretation of the results of antibody transfer experiments, our study not only provides experimental evidence for the arthritogenicity of autoantibodies to citrullinated CII but also evidence for such a role of ACPAs in general. Controlled experiments have so far not been able to show a specifi c response to citrullinated proteins in several investigated arthritis models, including spontaneous arthritis in lupus mice, streptococcal cell wall -induced arthritis, pristane-induced arthritis in rats, and in some reports of CIA in DBA/1 mice ( 5, 28 ). There are some notable exceptions of mouse experimental arthritides: one study that uses bovine CII in CFA for induction of CIA ( 29 ) , and another study of genetically engineered DBA/1 mice expressing human MHC class II molecules in the joints ( 30 ) . Recently, another study showed spreading of antibody responses to citrullinated proteins in CIA in the DBA/1 mice ( 31 ).
It also has been previously shown that the injection of monoclonal IgM and IgG antibodies reactive with citrullinated fi brinogen enhance the development of CAIA ( 29 ) . These antibodies were not cross-reactive with native CII, but it was not investigated if cross-reactivity to CII ␣ chains or to citrullinated CII could account for their arthritogenic eff ect.
In the present study, the crystal structure analysis elucidates important new information on the specifi city of the interaction between a mAb-derived Fab fragment and a citrullinated arginine in the conserved motif of a major CII epitope. Although the pCII-Cit1 peptide contains, besides the citrulline residue, fl anking sites that form the entire citrullinated B cell epitope (GACitGLTGRPGDA), the interpretable electron density only covers a shorter stretch (ACitGLTGRP) that peptides in solution. This energetically favored peptide conformation is also likely to contribute to the predominance of ␤ turns compared with other possible structures in peptideantibody complexes ( 32, 33 ) . Accordingly, the adoption of a ␤ turn by the pCII-Cit1 peptide in complex with the ACC4 Fab might follow a more general principle. However, the elucidation of the pCII-Cit1 conformation in the ACC4 complex might provide a clue to a better understanding underlying the pathophysiologically relevant functional aspect of cross-reactive autoantibody recognition. Thus, we previously described human IgG antibodies in RA sera that exhibit cross-reactivities between the citrullinated C1 epitope and citrullinated cyclized peptides ( 25 ) . Accordingly, we also detected a weak but signifi cant cross-reactivity of the mouse ACC4 mAb with the cyclic citrullinated fi laggrin peptide CCP1. It is therefore conceivable that the ␤ turn adopted by the pCII-Cit1 peptide provides a cyclic shape that is similar to that recognized by the ACC4 mAb in the fi laggrin peptide. Moreover, such ␤ turn motifs are frequently encountered within the fi laggrin sequences ( 34 ) . However, fi laggrin is not expressed in the joints, so autoantibody cross-reactivity to fi laggrin is unlikely to be relevant for joint pathology. On the other hand, type II ␤ turn motifs are quite diff erent from the native structure of CII, a putative candidate cartilage -specifi c autoantigen that has a characteristic structure of an extended helical coil wrapped in a triple helical conformation ( 35 -39 ) . This structural diff erence implies that those ACC mAbs capable of recognizing citrulline in the context of a triple helical conformation may diff er from ACC4 with regard to citrulline side chain recognition. Alternatively, citrullination of the collagen triple helix could provoke a weakening of its rigid structure that eventually allows the citrulline residue to protrude into the CDR regions of the antibody. Thus, the partial unfolding or denaturation by citrullination of particular arginine residues could represent a mechanism causing conformational changes of distinct domains of the triple helix into ␤ turns. In accordance, it has already been reported for noncollagenous proteins that citrullination can destabilize their tertiary structure and enhance their vulnerability to proteolytic digestion upon unfolding ( 34 ) . Thus, an analogous partial unfolding of the triple helix upon PAD-induced deimination of certain arginine residues remains an intriguing possibility to trigger arthritogenic CII autoimmunity by the introduction of primary as well as tertiary structural changes into the tolerated self-protein. In turn, activation of adaptive and innate immune responses in the joints causes infl ammation and proteolytic cartilage destruction with the subsequent liberation of native as well as denatured CII fragments into the synovium and synovial fl uid. Subsequently, these peptides may get enzymatically deiminated by PADs, particularly PAD4. In agreement with such a scenario, we could not only demonstrate the occurrence of citrullinated CII in mouse cartilage and infl amed synovial tissue by immunohistology but also in synovial fl uid specimens from RA patients. However, detection of these modifi ed CII fragments also occurs in OA, thereby emphasizing that it is the extends in length to the previously described noncitrullinated CII epitope C1 ( 24 ) . The analysis of the crystal further uncovers that the citrulline is buried within the antibody-combining sites and is recognized via interactions with the CDR1 and CDR2 regions of the V H chain, whereas the collagen strand forms a distinct stable ␤ hairpin with a type II ␤ turn conformation. Thus, the bound CII peptide considerably diff ers from the deposited characteristic structures of triple helical collagen peptides in the database.
Adoption of a ␤ hairpin is energetically more stable, and is therefore expected to be the preferred conformation of The CDR regions are determined according to IMGT rules. Residues that contact arginine7P are bolded. The residues that contact citrulline2P are underlined. FR, framework region.
at position 360 (GP-HyP-GACitGLTGR-HyP -GDAGP-HyP), peptide pCII-Cit2 has a citrulline at position 365 (GP-HyP-GARGLTGCit-HyP -GDAGP-HyP), and peptide pCII-Cit1+2 has citrulline residues at both position 360 and 365 (epitopes are denoted in bold). The triple helical peptide THPCII-Arg contains the C1 epitope of mouse CII in its triple helical form (GP-HYP-GP-HYP-GP-HYP-GP-HYP-GP-HYP-GARGLTGR-HyP-GDAGP-HyP-GP-HYP-G-ACA) ( 3 ), and the citrullinated version of the peptide, THPCII-Cit, has citrullines at both position 360 and 365. A citrullinated cyclic (cyc) fi laggrin peptide ( 47 ), cyc-Cit (HQ C HQEST (cit) GRS RGR C GRSGS; cit, citrulline; C , cysteines forming the disulfi de bond upon oxidative cyclization), and a respective noncitrullinated peptide analogue, cyc-Arg (HQ C HQEST R GRSRGR C GRSGS) ( 47 ), were obtained as commercially synthesized reagents (mass spectrometrically confi rmed peptide identity and fast protein liquid chromatography -controlled purity > 98%; Herman GbR Synthetische Biomolek ü le). Fibrinogen and citrullinated fi brinogen were isolated as previously described in detail ( 48 ) .
Generation of mAbs and induction of CAIA. The CII-specifi c hybridomas have been previously generated and characterized ( 25, 46 ) . The ACC1 hybridoma was established by immunizing and boosting a Cia5 congenic B10.RIII mouse ( 47 ) at the base of the tail with 100 or 50 μ g of bovine CII in CFA or IFA (Difco), respectively. The other ACC hybridomas were produced using PAD4-treated triple helical CII peptides containing T and B cell epitopes for immunization and boosting of DBA/1 or (B10.Q × DBA/1) F1 mice. The GB8 and ACC5 clones originated from B10.Q mice, which had chronic arthritis after CII/CFA immunization. Specifi city selection was done using native or denatured CII, CII peptides, and single and triple helical citrullinated or native C1 epitopes. mAbs were produced and purifi ed as previously described ( 48 ) . CAIA was induced in naive mice using a standard procedure ( 48 ) , and antibody-induced relapses were induced as previously described ( 49 ).
ELISA.
For the characterization of the mAbs, either antigen-coated maxisorp immuno plates (Thermo Fisher Scientifi c) or biotinylated antigens linked to the plates via 2 μ g/ml NeutrAvidin (PerkinElmer) were used. The direct coating of 10 μ g/ml of antigens in PBS was used for the following polypeptides: heat-denatured (60 ° C for 15 min) CII (dCII-Arg), PAD4-treated CII (dCII-Cit), and native triple helical CII (nCII-Arg). The antigens cyc-Cit (citrullinated cyclic fi britin peptide), cyc-Arg (cyclic fi britin peptide), THPCII-Cit, and THPCII-Arg at 4 μ g/ml, and Fib-Arg and FibCit at 0.5 μ g/ml were used for coating in PBS. All plates were blocked using 2% BSA (Sigma-Aldrich). After washing in Tris-based ELISA buff er, serial dilutions of the mAbs starting at 1,000 ng/ml were added and incubated for 2 h at room temperature. The light chain -specifi c mAb 187.1-biotin or goat anti -mouse IgM -biotin and SA-Eu+3 (PerkinElmer) were used for detection. The indirect coating via NeutrAvidin was used for the following antigens: biotinylated pCII-Arg, biotinylated pCII-Cit1, biotinylated pCIICit2, and biotinylated pCII-Cit1+2 at a concentration of 4 μ g/ml in PBS.
Plates were blocked and washed before serial dilutions of antibodies were added. Horseradish peroxidase -conjugated goat anti -mouse -IgG (Jackson ImmunoResearch Laboratories) or goat anti -mouse -IgM (SouthernBiotech) antibodies and ABTS tablets (Roche) were used for detection. immune response to the citrullinated peptide that is unique for RA rather than the deimination of joint proteins, which is in support of previous fi ndings ( 40 ) . Citrulline modifi cation within the structural frame of a relatively stable conformation such as a ␤ turn or a triple helix may help to activate B cells. Importantly, activation of B cells that fi nally lead to the generation of highly specifi c IgG antibodies depends on appropriate T cell help. This requirement also applies to the induction of arthritogenic responses by CII-specifi c B cells that receive activating signals from CIIspecifi c T cells recognizing an immunodominant determinant on CII that diff ers from the respective B cell epitopes ( 22, 41, 42 ) . In both mice with the A q MHC class II molecules or in humans with RA-associated shared-epitope MHC class II variants, this critical CII determinant has been localized to the domain 261 -271 that harbors a galactosylated lysine side chain that is critical for T cell receptor recognition ( 20, 43 ) . It is highly likely that the same type of T cell specifi city can also trigger B cell responses to the presently studied citrullinated CII epitopes because they are found on the same protein backbone as the immunodominant C1 epitope on CII.
Humoral immune response to citrullinated proteins precedes the development of RA and is genetically associated with MHC class II alleles that confer increased risk for disease onset and severity ( 44, 45 ) . In this context, our results suggest that the autoantibody responses to citrullinated proteins are likely to play a critical pathogenic role beyond their unequivocal value as early diagnostic markers. Their involvement in cross-reactive hapten-carrier mechanisms may lead to the activation of pathogenic B and T cells reactive with native and posttranslationally modifi ed CII, thereby initiating an amplifying vicious circle of infl ammatory responses in the joints. Furthermore, it is of interest to note that anticitrulline antibodies can also play an important role in inducing antibodymediated arthritic relapses that could be of potential importance for future therapeutic intervention during the chronic phase of arthritis in both animals and humans.
To summarize, we have demonstrated the molecular structure of the specifi c interactions between an antibody and a citrullinated antigen and have shown that this interaction will have pathogenic consequences in vivo. We believe this will be useful for understanding the functional role of the antibody response to citrullinated proteins in RA and points toward a specifi c link to CII as one of the relevant self-antigens involved.
MATERIALS AND METHODS
Animals. All mice used in this study were bred in the animal facilities of the Section for Medical Infl ammation Research at Lund University, but the original founders for the B10.Q/rhd and B10.RIII/rhd mice were from University of T ü bingen, and the original founders for the BALB/cJ mice were from the Jackson Laboratory. All animals were treated according to the Swedish guidelines for humane treatment of laboratory animals, and the experiments were approved by the Lund-Malm ö laboratory animal ethical committee.
Peptides and proteins.
The following linear and triple helical peptides were synthesized using methods previously described in detail ( 23, 46 ) . The linear peptide pCII-Arg contains the C1 epitope of mouse CII (GP-HyP-GARGLTGR-HyP -GDAGP-HyP), the peptide pCII-Cit1 has a citrulline Crystallization. 10 mg/ml ACC4 Fab in 30 mM of Tris buff er (pH 8) with and without the pCII-Cit1 peptide was crystallized using the hanging drop method using a Peg/Ion screen (Hampton Research). For Fab -peptide complex crystallization, the collagen peptide and Fab were mixed at a 5:1 molar ratio and incubated at 4 ° C overnight. Crystallization drops containing 2 μ l of mother liquor and 2 μ l of protein solution were incubated at 25 ° C. Crystals of the Fab -peptide complex appeared only in two conditions (#31 and #36), whereas crystals of the Fab alone appeared in several conditions. Promising conditions were optimized by decreasing the salt concentration and by adding glycerol. A crystal of the Fab -peptide complex grown in 0.15 M ammonium sulfate, 20% PEG 3350, and 10% glycerol was used for data collection, whereas for determining Fab structure, a crystal grown in 0.15 M ammonium nitrate and 25% PEG 3350 was used for data collection.
Data collection. Datasets were collected at the I911-2 and I911-5 beam lines at MAX-lab. Before data collection, the crystals were soaked in a cryoprotecting solution of 20% glycerol (vol/vol) and mother liquor before exposure to synchrotron radiation. The crystals were fl ash cooled and data were collected at 100K. The noncomplex crystals diff racted to 1.5 Å and crystals of the complex diff racted to 2.1 Å . Both datasets were processed by XDS ( 53 ) , and further data manipulation was performed using programs from the CCP4 suite ( 54 ) . Crystal parameters and statistics from the data collection are shown in Table IV .
Structure determination and refi nement. The structures of the complex and noncomplex forms of the antibody were solved by molecular replacement using PHASER ( 55 ) . The structure of anticollagen CIIC1 Fab ( 56 ) was used as a searching model. The model was split into variable and constant domains, and searching and fi xing of these domains separately gave a single solution with an R free of 46%. For solving the ACC4 Fab -peptide complex structure, the ACC4 Fab structure was used intact as a search model. A single solution with an R free of 45% was obtained. Mismatching residues from the search model were changed to ACC4 residues, and missing loops were built by using the program COOT ( 57 ) . Further refi nement was performed by REFMAC ( 58 ) in the CCP4 suite ( 54 ) . Restrained and TLS ( 59 ) refi nement helped to decrease the R factor and R free to respectable values. For the refi nement of the Fab -peptide complex structure, noncrystallographic symmetry restraints were applied. Two sulfate ions were identifi ed in the model for the complex and one nitrate ion was added to the noncomplex Fab model. For building, the ligand Fo-Fc maps were calculated and the peptide was built into the positive density. In the fi nal stage, water molecules were added to the models. Data and refi nement statistics are shown in Table IV . The coordinates of the structures are available from the Protein Data Bank under accession nos. 2w60 and 2w65 .
Online supplemental material. Fig. S1 shows the amino acid sequences of antibody CDR regions, corresponding germline genes, and mouse strains that antibodies originated. Fig. S2 shows an amino acid sequence comparison of the CDR regions of the sequenced antibodies. Fig. S3 contains a stereoscopic view of the pCII-Cit1 peptide. Table S1 shows the somatic mutation statistics in light and heavy chains of antibodies. Supplemental materials and methods describes the DNA sequencing procedures. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20081862/DC1.
Immunoprecipitation of citrullinated CII from synovial fl uid. Immunoprecipitation was performed using earlier characterized mouse IgG mAbs specifi c for distinct triple helical CII epitopes (CIIE10, M2139, and CIID3) ( 24 ) and a protein G immunoprecipitation kit (Seize X; Thermo Fisher Scientifi c). 500 μ g IgG (166 μ g of each mouse mAb) was covalently cross-linked to 400 μ l of protein G slurry according to the manufacturer ' s instructions. 40 μ l anti-CII -IgG cross-linked beads were added to 4 ml of RA synovial fl uid (diluted 1:1 in binding buff er) and incubated overnight at 4 ° C. Upon centrifugation, the immunoprecipitated CII was eluted from the protein G slurry and 20 μ l of each fraction was applied to an SDS gel for Western blot analysis.
Citrullinated CII was detected using the modifi ed citrulline Western blot detection kit (Millipore). Alternatively, in-gel Western blot detection of immunoprecipitated citrullinated CII was performed using the citrullinespecifi c biotinylated ACC2 antibody and avidin-peroxidase (Sigma). For visualization of the results, an ECL plus detection kit (Millipore) was applied.
Capture ELISA for citrullinated CII in synovial fl uid. ELISA plates were coated with the CII-specifi c antibodies CIIE10, M2139, and CIID3 in PBS (2 μ g/ml each). Subsequently, 100-μ l specimens of hyaluronidase-pretreated synovial fl uid were incubated for 90 min at room temperature. Incubation with BSA served as a negative control. Upon thorough washings, 0.3 μ g/ml of the biotinylated ACC2 was added for 90 min at room temperature. Development was performed using avidin-peroxidase at a dilution of 1:750 in 1% BSA/PBS and ABTS as substrate. All assays were run in triplicates.
Immunohistochemistry and histopathology. Paws from naive 4-moold male BALB/c or (BALB/c × B10.Q) F1 mice injected with 9 mg of arthritogenic anti-CII mAbs (M2139 and CIIC1) on day 11 were decalcifi ed for 4 wk in an EDTA solution and frozen in optimum cutting temperature compound using isopentane on dry ice. The samples were stored at Ϫ 70 ° C until cryosectioned at 10 μ m at Ϫ 30 ° C. Joint sections were stained with a panel of biotinylated anti-CII citrulline-specifi c mAbs (ACC1 -4). Streptavidin peroxidase was used for detection. Diaminobenzidine staining was performed according to established procedures.
Statistics. Statistical diff erence in the frequency (incidence) of disease between groups of mice was determined using a 2 analysis on all scoring days. To compare the mean arthritis score between two experimental groups, the nonparametric Mann-Whitney U test was used. All of the statistical analyses were performed using the StatView program (version 1; SAS Institute), and P < 0.05 was considered signifi cant.
Preparation of ACC4 Fab. ACC4 Fab fragments were prepared by using an ImmunoPure Fab Preparation Kit (Thermo Fisher Scientifi c) according to the manufacturer ' s instructions. In brief, 20 mg of ACC4 antibody was concentrated and diluted with 20 mM sodium phosphate and 10 mM EDTA buff er (pH 7) several times by using centrifugal fi lter devices (Amicon Ultra; Millipore). 20 mg of concentrated IgG was mixed with 0.5 ml of immobilized papain. The mixture was incubated by shaking overnight at 37 ° C. Crude digest was separated from immobilized papain and applied to a protein A column (Affi nityPak; Thermo Fisher Scientifi c). Fab fragments were recovered in the fl ow through. Fc fragments and undigested IgG bound to the column were eluted with elution buff er. Collected Fab fragments were concentrated and further gel fi ltered on a Superdex 200 (10/30) column (GE Healthcare). The gel fi ltration column was previously equilibrated with 30 mM of Tris buff er (pH 8).
Antibody V gene sequence analysis. The cDNA sequences of the heavy and light chains of anticollagen-and citrulline-specifi c antibodies were sequenced (see Supplemental materials and methods, available at http://www .jem.org/cgi/content/full/jem.20081862/DC1) and analyzed by IMGT/V-QUEST ( 50 ) and IMGT/Junction Analysis ( 51 ) from the IMGT database ( 52 ) , and IgBLAST from the National Center for Biotechnology Information (available from GenBank/EMBL/DDBJ under accession nos. EU159566 , EU159567 , EU159568 , EU159569 , EU159570 , EU159571 , EU159572 , EU159573 , EU159574 , EU159575 , EU159576 , and EU159577 ; Fig. S1 ).
